RxDoctor Payments Data

Jeffrey Buehrer, MD

Vascular Surgery · Sandusky, OHNPI 1063405280

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,043 of the $9,997 with a category attached, or 60.5%. 28 manufacturers reported payments, led by Medtronic at 58.7% of the total. Reporting peaked in 2022 at $5,697 and has fallen 92.9% since, to $407 in 2025.

$9,997in general payments, 2019–2025

Across 85 payments — averaging $117.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Silk Road Medical, Inc.$1K
  • Biotissue Holdings Inc.$690
  • Endologix LLC$528
  • Inari Medical, Inc.$287
  • Abbott$239
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$6,04360%
  • Food & beverage$3,95340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,997 in reported general payments places this provider in the 75th percentile of 213 vascular surgery providers in Ohio.

See all vascular surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$165,954
Medicare patients
818
Services billed
1,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban18$20,467
EliquisApixaban14$10,450
ClopidogrelClopidogrel Bisulfate86$1,244
Atorvastatin Calcium20$172
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$210$20,46718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 213 vascular surgery providers in Ohio.

Other vascular surgery in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →